The price-to-earnings ratio for Dynavax Technologies Corp (NASDAQ: DVAX) is above average at 65.31x, Company’s 36-month beta value is 1.28.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DVAX is 118.47M, and currently, short sellers hold a 15.53% ratio of that floaft. The average trading volume of DVAX on April 16, 2025 was 2.38M shares.
DVAX) stock’s latest price update
The stock of Dynavax Technologies Corp (NASDAQ: DVAX) has decreased by -0.26 when compared to last closing price of 11.44. Despite this, the company has experienced a -2.89% fall in its stock price over the last five trading sessions. prnewswire.com reported 2025-04-03 that Dynavax’s Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif., April 3, 2025 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today filed its preliminary proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming Annual Meeting of Stockholders (“the 2025 Annual Meeting”).
DVAX’s Market Performance
Dynavax Technologies Corp (DVAX) has experienced a -2.89% fall in stock performance for the past week, with a -16.29% drop in the past month, and a -8.57% drop in the past quarter. The volatility ratio for the week is 5.23%, and the volatility levels for the past 30 days are at 3.90% for DVAX. The simple moving average for the last 20 days is -10.60% for DVAX stock, with a simple moving average of -5.59% for the last 200 days.
Analysts’ Opinion of DVAX
Many brokerage firms have already submitted their reports for DVAX stocks, with Goldman repeating the rating for DVAX by listing it as a “Sell.” The predicted price for DVAX in the upcoming period, according to Goldman is $12 based on the research report published on February 11, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see DVAX reach a price target of $20. The rating they have provided for DVAX stocks is “Neutral” according to the report published on February 01st, 2024.
JMP Securities gave a rating of “Mkt Outperform” to DVAX, setting the target price at $22 in the report published on September 27th of the previous year.
DVAX Trading at -13.47% from the 50-Day Moving Average
After a stumble in the market that brought DVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.01% of loss for the given period.
Volatility was left at 3.90%, however, over the last 30 days, the volatility rate increased by 5.23%, as shares sank -17.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.82% lower at present.
During the last 5 trading sessions, DVAX fell by -2.89%, which changed the moving average for the period of 200-days by +0.35% in comparison to the 20-day moving average, which settled at $12.76. In addition, Dynavax Technologies Corp saw -10.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DVAX starting from Novack David F, who sale 10,000 shares at the price of $14.00 back on Mar 24 ’25. After this action, Novack David F now owns 8,078 shares of Dynavax Technologies Corp, valued at $140,000 using the latest closing price.
DAVID NOVACK, the Officer of Dynavax Technologies Corp, proposed sale 10,000 shares at $14.00 during a trade that took place back on Mar 24 ’25, which means that DAVID NOVACK is holding shares at $140,000 based on the most recent closing price.
Stock Fundamentals for DVAX
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.82 for the gross margin
The net margin for Dynavax Technologies Corp stands at 0.1. The total capital return value is set at -0.0. Equity return is now at value 4.48, with 2.75 for asset returns.
Based on Dynavax Technologies Corp (DVAX), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.43. The interest coverage ratio of the stock is -0.35.
Currently, EBITDA for the company is 45.7 million with net debt to EBITDA at 4.79. When we switch over and look at the enterprise to sales, we see a ratio of 5.69. The receivables turnover for the company is 5.91for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.80.
Conclusion
In a nutshell, Dynavax Technologies Corp (DVAX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
